Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) to Post FY2024 Earnings of ($0.67) Per Share, Wedbush ForecastsZolmax • 26 days ago
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Equities researchers at Wedbush decreased their FY2024 EPS estimates for shares of Kiniksa Pharmaceuticals in a research report issued to...
Share to Feed
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA - Free Report) - Investment analysts at Wedbush decreased their FY2027 earnings per share (EPS) estimates for shares of Kiniksa Pharmaceuticals in a...
Abiprubart Phase 2b trial in Sjogren's Disease planned to initiate in 2H 2024 Abiprubart Phase 2 Cohort 4 rheumatoid arthritis data further validate biological activity Abiprubart development...
Goldman Sachs analyst Paul Choi maintained a Buy rating on Kiniksa Pharmaceuticals (KNSA Research Report) today. The company's shares opened toda...
This is a signal that KNSA's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...
This indicator may be signaling that KNSA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Over the last three days, A.I.dvisor has detected that KNSA's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...
This indicator may be signaling that KNSA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...
Over the last three days, A.I.dvisor has detected that KNSA's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...
Over the last three days, A.I.dvisor has detected that KNSA's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...